Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
- PMID: 35720001
- PMCID: PMC9200965
- DOI: 10.3389/fonc.2022.921667
Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
Abstract
Hepatocellular carcinoma (HCC) has the third-highest incidence in cancers and has become one of the leading threats to cancer death. With the research on the etiological reasons for cirrhosis and HCC, early diagnosis has been placed great hope to form a favorable prognosis. Non-invasive medical imaging, including the associated contrast media (CM)-based enhancement scan, is taking charge of early diagnosis as mainstream. Meanwhile, it is notable that various CM with different advantages are playing an important role in the different imaging modalities, or even combined modalities. For both physicians and radiologists, it is necessary to know more about the proper imaging approach, along with the characteristic CM, for HCC diagnosis and treatment. Therefore, a summarized navigating map of CM commonly used in the clinic, along with ongoing work of agent research and potential seeded agents in the future, could be a needed practicable aid for HCC diagnosis and prognosis.
Keywords: CECT; MRI; contrast media (CM); hepatocellular carcinoma (HCC); ultrasound.
Copyright © 2022 Zhang, Numata, Du and Maeda.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. . Cancer Statistics for the Year 2020: An Overview. Int J Cancer (2021). - PubMed
Publication types
LinkOut - more resources
Full Text Sources
